» Articles » PMID: 31163278

Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium

Abstract

Introduction: The relationships between morbid obesity, changes in body mass index (BMI) before cancer diagnosis, and lung cancer outcomes by histology (SCLC and NSCLC) have not been well studied.

Methods: Individual level data analysis was performed on 25,430 patients with NSCLC and 2787 patients with SCLC from 16 studies of the International Lung Cancer Consortium evaluating the association between various BMI variables and lung cancer overall survival, reported as adjusted hazard ratios (aHRs) from Cox proportional hazards models and adjusted penalized smoothing spline plots.

Results: Overall survival of NSCLC had putative U-shaped hazard ratio relationships with BMI based on spline plots: being underweight (BMI < 18.5 kg/m; aHR = 1.56; 95% confidence interval [CI]:1.43-1.70) or morbidly overweight (BMI > 40 kg/m; aHR = 1.09; 95% CI: 0.95-1.26) at the time of diagnosis was associated with worse stage-specific prognosis, whereas being overweight (25 kg/m ≤ BMI < 30 kg/m; aHR = 0.89; 95% CI: 0.85-0.95) or obese (30 kg/m ≤ BMI ≤ 40 kg/m; aHR = 0.86; 95% CI: 0.82-0.91) was associated with improved survival. Although not significant, a similar pattern was seen with SCLC. Compared with an increased or stable BMI from the period between young adulthood until date of diagnosis, a decreased BMI was associated with worse outcomes in NSCLC (aHR = 1.24; 95% CI: 1.2-1.3) and SCLC patients (aHR=1.26 (95% CI: 1.0-1.6). Decreased BMI was consistently associated with worse outcome, across clinicodemographic subsets.

Conclusions: Both being underweight or morbidly obese at time of diagnosis is associated with lower stage-specific survival in independent assessments of NSCLC and SCLC patients. In addition, a decrease in BMI at lung cancer diagnosis relative to early adulthood is a consistent marker of poor survival.

Citing Articles

Non-cancerous CT findings as predictors of survival outcome in advanced non-small cell lung cancer patients treated with first-generation EGFR-TKIs.

Prakaikietikul P, Tajarenmuang P, Losuriya P, Ina N, Ketpueak T, Kanthawang T PLoS One. 2025; 20(2):e0313577.

PMID: 39908320 PMC: 11798445. DOI: 10.1371/journal.pone.0313577.


First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis.

Zhang M, Sun L Front Oncol. 2025; 14:1498518.

PMID: 39882445 PMC: 11774708. DOI: 10.3389/fonc.2024.1498518.


Clinical and imaging features of co-existent pulmonary tuberculosis and lung cancer: a population-based matching study in China.

Zhang F, Qi F, Han Y, Yang H, Wang Y, Wang G BMC Cancer. 2025; 25(1):89.

PMID: 39815214 PMC: 11734471. DOI: 10.1186/s12885-024-13350-y.


Completing the Puzzle: Determinants, Comorbidities and Complications for Different Lung Cancer Subtypes: A Pilot Study.

Budin C, Cocuz I, Sabau A, Niculescu R, Cazacu C, Ianosi E Life (Basel). 2025; 14(12.

PMID: 39768319 PMC: 11676267. DOI: 10.3390/life14121611.


Association Between Body Mass Index and Survival in Patients with De Novo Metastatic Non-Small Cell Lung Cancer.

Urun M, Guner G, Sezgin Y, Sakin A, Kilickap S Med Sci Monit. 2024; 30:e946751.

PMID: 39690723 PMC: 11665478. DOI: 10.12659/MSM.946751.


References
1.
Gupta A, Majumder K, Arora N, Mayo H, Paul Singh P, Beg M . Premorbid body mass index and mortality in patients with lung cancer: A systematic review and meta-analysis. Lung Cancer. 2016; 102:49-59. DOI: 10.1016/j.lungcan.2016.10.017. View

2.
Bowden J, Williams L, Simms A, Price A, Campbell S, Fallon M . Prediction of 90 Day and Overall Survival after Chemoradiotherapy for Lung Cancer: Role of Performance Status and Body Composition. Clin Oncol (R Coll Radiol). 2017; 29(9):576-584. DOI: 10.1016/j.clon.2017.06.005. View

3.
Soo R, Kawaguchi T, Loh M, Ou S, Shieh M, Cho B . Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. Future Oncol. 2012; 8(4):451-62. DOI: 10.2217/fon.12.25. View

4.
Nakagawa T, Toyazaki T, Chiba N, Ueda Y, Gotoh M . Prognostic value of body mass index and change in body weight in postoperative outcomes of lung cancer surgery. Interact Cardiovasc Thorac Surg. 2016; 23(4):560-6. DOI: 10.1093/icvts/ivw175. View

5.
Renehan A, Harvie M, Cutress R, Leitzmann M, Pischon T, Howell S . How to Manage the Obese Patient With Cancer. J Clin Oncol. 2016; 34(35):4284-4294. DOI: 10.1200/JCO.2016.69.1899. View